Marked increase in steady-state serum levels achieved with itraconazole oral solution compared with capsule formulation

被引：3

作者：

Freeman, Josh

Heshmati, Amy

Holland, David

Ticehurst, Rob

Lang, Selwyn

机构：

[1] Middlemore Hosp, Dept Microbiol, Cty Maukau Dist Hlth Board, Auckland 6, New Zealand

[2] Middlemore Hosp, Clin Pharm Serv, Cty Maukau Dist Hlth Board, Auckland 6, New Zealand

[3] Middlemore Hosp, Clin Pharm Serv, Cty Manukau Dist Hlth Board, Auckland 6, New Zealand

[4] Middlemore Hosp, Dept Internal Med Infect Med, Cty Manukau Dist Hlth Board, Auckland 6, New Zealand

[5] Auckland Dist Hlth Board, Clin Pharm Serv, Auckland, New Zealand

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2007年 / 60卷 / 04期

关键词：

D O I：

10.1093/jac/dkm272

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

引用

页码：908 / 909

页数：3

共 7 条

[1] Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients [J].

Buchkowsky, SS ;

Partovi, N ;

Ensom, MHH .

THERAPEUTIC DRUG MONITORING, 2005, 27 (03) :322-333

[2]

*INF HEALHTC PROF, 2006, SPOR CAPS DAT

[3]

*INF HEALTHC PROF, 2006, SPOR OR SOL

[4] Antifungal activity of itraconazole compared with hydroxy-itraconazole in vitro [J].

Odds, FC ;

Bossche, HV .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 (03) :371-373

[5]

Poirier JM, 1996, THERAPIE, V51, P163

[6] Optimisation of itraconazole therapy using target drug concentrations [J].

Poirier J.-M. ;

Cheymol G. .

Clinical Pharmacokinetics, 1998, 35 (6) :461-473

[7]

REDMANN S, 2004, CLIN EXP PHARM PH S1, V31, pA107

← 1 →